Bibliography

Websites

Journals and abstracts

Report methodology

Datamonitor forecast methodology

Sales calculations

About Datamonitor

Market Forecast Data

Global forecasts

US forecasts

Japan forecasts

MEU5 forecasts

France forecasts

Germany forecasts

Italy forecasts

Spain forecasts

UK forecasts

List of Tables

Table 1: Revenue forecast of ADHD drugs across the seven major markets, 2005-15

Table 2: Revenues of ADHD drugs across the seven major markets, 2004

Table 3: Revenues of ADHD drugs in the US, 2004

Table 4: Revenues of ADHD drugs in Japan, 2004

Table 5: Revenues of ADHD drugs in France, 2004

Table 6: Revenues of ADHD drugs in Germany, 2004

Table 7: Revenues of ADHD drugs in Spain, 2004

Table 8: Revenues of ADHD drugs in the UK, 2004

Table 9: J&J's US marketed CNS portfolio

Table 10: J&J's CNS R&D pipeline, 2005

Table 11: Child and adult revenues ($m) of ADHD drugs in the US market, 2001-04

Table 12: Child and adult revenues ($m) of ADHD drugs in the EU and Japan, 2001-04

Table 13: Strattera key facts

Table 14: Key Strattera events, 2004-2005

Table 15: Adderall and Adderall XR key facts

Table 16: Key Adderall and Adderall XR events, 2004-2005

Table 17: Concerta key facts

Table 18: Key Concerta events, 2004-2005

Table 19: Ritalin franchise key facts

Table 20: Dexedrine and Dexedrine SR key facts

Table 21: Dextrostat key facts

Table 22: Focalin key facts

Table 23: Key Focalin franchise events, 2004-2005

Table 24: Metadate franchise key facts

Table 25: Key Metadate franchise events, 2003-2005

Table 26: Global ADHD market forecasts (2005-2015) ($m)

Table 27: US ADHD market forecasts (2005-2015) ($m)

Table 28: Japan ADHD market forecasts (2005-2015) ($m)

Table 29: MEU5 ADHD forecasts (2005-2015) ($m)

Table 30: France ADHD market forecasts (2005-2015) ($m)

Table 31: Germany ADHD market forecasts (2005-2015) ($m)

Table 32: Italy ADHD market forecasts (2005-2015) ($m)

Table 33: Spain ADHD market forecasts (2005-2015) ($m)

Table 34: UK ADHD market forecasts (2005-2015) ($m)

List of Figures

Figure 1: Revenues of currently branded stimulants, atomoxetine, generics and pipeline ADHD drugs, 2001-15

Figure 2: Revenue market share of the leading branded ADHD drugs, 1999-2004

Figure 3: Seven major market revenue forecast of J&J's ADHD franchise to 2015

Figure 4: Seven major market revenue forecast of Shire's ADHD franchise to 2015

Figure 5: Seven major market revenue forecast of Novartis' ADHD franchise to 2015

Figure 6: Seven major market revenue forecast of UCB's ADHD franchise to 2015

Figure 7: Seven major market revenue forecast of Lilly's ADHD franchise to 2015.

Figure 8: Revenue growth, market share and revenues of leading ADHD drugs across the seven major markets, 2003-04

Figure 9: ADHD drug revenue market share of leading manufacturers, 2001-15

Figure 10: ADHD drug revenues of leading manufacturers, 2001-15

Figure 11: Key players in the ADHD market

Figure 12: NICE method for measuring cost-effectiveness of drug treatment for ADHD

Figure 13: Most cost-effective treatment of ADHD in the UK

Figure 14: Shire's damage limitation strategy for Adderall XR

Figure 15: Shire's on-line Adderall XR patient questionnaire

Figure 16: Global quarterly revenues of Strattera since launch and key lifecycle events

Figure 17: US revenues of the market-leading ADHD drugs, 2002-05

Figure 18: Adult revenues ($m) of ADHD drugs in the US market, 2001-04

Figure 19: Comparison of ADHD promotion of Strattera and Adderall XR home pages

Figure 20: US drug revenues, 2001-04

Figure 21: Monthly growth and decline of US drug revenues over time, 2001-04

Figure 22: Revenue growth of ADHD drug form launch

Abstract